BioSino Bio-Technology And Science Inc.（中生北控生物科技股份有限公司） - Leading Chinese IVD Reagent Manufacturer

📢 Key Milestones (2024–2026):
   In May 2025, President and Executive Director Chen Peng was released from detention and resumed his duties after completing an investigation. In July 2025, former Chairman Wu Lebin was formally removed from all directorships following his detention and disappearance since November 2024. In February 2026, Chen Peng was appointed Chairman of the Board, and the company celebrated its 20th listing anniversary. In March 2025, the company obtained CNAS accreditation for its medical reference laboratory.

Company Profile (Updated April 2026)

BioSino Bio-Technology And Science Inc. (Chinese: 中生北控生物科技股份有限公司) is a China-based in-vitro diagnostics (IVD) company specializing in the research, development, manufacturing, sales, and distribution of clinical diagnostic reagents and related medical instruments. The company was established on April 26, 2001, and its H-shares have been listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong since 2006 under stock code 8247.

The group is headquartered in Beijing, china, with its principal office at No. 27 Chaoqian Road, Changping Science Park, Beijing, and maintains a Hong Kong office at 66/F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong. The company primarily serves hospitals and medical institutions across mainland China, with expanding export activities in Southeast Asia and other regions.

Development History:

- 1988: Origins trace back to the founding of the predecessor entity by Wu Lebin, connected with the Chinese Academy of Sciences (CAS) Institute of Biophysics

- 2001.04.26: BioSino Bio-Technology And Science Inc. formally established as a joint stock company

- 2006: H-shares successfully listed on the Hong Kong Stock Exchange GEM (Stock Code: 8247)

- 2014: Wu Lebin transitioned to serve as Secretary of the Party Committee of CAS Enterprises and Chairman of CAS Holdings

- 2021.12: Chen Peng appointed as President of the company

- 2023.05: Chen Peng appointed as Executive Director

- 2024.06: He Xin appointed as Independent Non-Executive Director

- 2024.11: Chairman Wu Lebin and President Chen Peng became unreACHAble; subsequently placed under detention/investigation by Chinese authorities

- 2024.12: Chen Zhengyong transferred from Non-Executive Director to Executive Director and Vice Chairman to assume interim leadership responsibilities

- 2025.03: Obtained CNAS (China National Accreditation Service) accreditation for the medical reference laboratory

- 2025.05.30: Chen Peng released from detention and resumed duties as President and Executive Director

- 2025.07.15: Shareholders' extraordinary general meeting formally removed Wu Lebin from all directorships; Chen Zhengyong appointed as authorized representative

- 2026.02.09: Chen Peng appointed Chairman of the Board; Kang Rui appointed as Non-Executive Director; Professor Jin Tengchuan appointed as Independent Non-Executive Director

- 2026.02: Celebrated 20th anniversary of Hong Kong listing

Core Mission: To provide high-quality, reliable in-vitro diagnostic reagent products and services to hospitals and medical institutions, contributing to disease detection and patient care across China and international markets.

Core Products & Business Scope

Clinical Chemistry Reagents

- Single and Double Reagents: Liquid and dry powder reagents for liver function, renal function, lipids, cardiac markers, glucose metabolism, inorganic ions, pancreatic disease, and special protein diagnostics

- Calibrators and Quality Control Products: Reference materials for diagnostic accuracy assurance

- Washing Solutions and Detergents: Consumables for automated analyzers

Immunoassay Products

- ELISA Kits: Tumor marker series, infectious disease series, thyroid function series, sex hormone series, and diabetes markers

- Rapid Test Products: Point-of-care diagnostic solutions

Molecular Diagnostic & Other Products

- Molecular Diagnostic Reagents: Genetic and nucleic acid testing products

- Hematology Reagents: Blood cell analysis reagents

- Medical Inspection Services: Third-party testing and laboratory services

- Diagnostic Analyzers: Automated clinical chemistry and immunoassay instruments

Financial Performance

FY2025 Results (Year Ended December 31, 2025)

Revenue: Approximately RMB 184.3 million (down ~30% year-on-year from RMB 263.1 million in FY2024)

Loss for the Year: Approximately RMB 67.2 million (compared to RMB 59.7 million loss in FY2024)

Loss Attributable to Owners: Approximately RMB 51.1 million (compared to RMB 42.5 million in FY2024)

Basic Loss Per Share: RMB -0.354

Dividend: No dividend recommended for FY2025

FY2024 Results (Year Ended December 31, 2024)

Revenue: Approximately RMB 263.1 million (down ~9.0% year-on-year)

Gross Profit: Approximately RMB 108.4 million; Gross Margin: ~41.2%

Loss for the Year: Approximately RMB 59.7 million

Loss Attributable to Owners: Approximately RMB 42.5 million

H1 2025 Results (Six Months Ended June 30, 2025)

Revenue: RMB 95.8 million (down 28.4% year-on-year)

Gross Profit: RMB 37.4 million (down 36.1% year-on-year)

Employees: 471 full-time employees (as of June 30, 2025; compared to 554 in June 2024)

Five-Year Financial Summary

- 2021: Revenue RMB 348.2 million; Profit RMB 6.4 million

- 2022: Revenue RMB 373.1 million; Profit RMB 18.5 million

- 2023: Revenue RMB 289.1 million; Loss RMB 17.6 million

- 2024: Revenue RMB 263.1 million; Loss RMB 59.7 million

- 2025: Revenue RMB 184.3 million; Loss RMB 67.2 million

Corporate Governance & Leadership

Board of Directors (As of February 2026)

- Chen Peng (陈鹏): Chairman of the Board, Executive Director, President; age 52; holds a bachelor's degree in integrated clinical medicine from Anhui University of Chinese Medicine (1998); previously served as Technical Director at Shanghai Fosun High Technology Group; appointed Chairman on February 9, 2026

- Chen Zhengyong (陈正永): Executive Director, Vice Chairman; holds 77.94% of Sichuan Zhongsheng Medical Equipment

- Li Zhonghua (李忠华): Executive Director, Vice Chairman

- Yang Peng (杨鹏): Non-Executive Director, Vice Chairman

- Gao Guangxia (高光侠): Non-Executive Director, PhD

- Kang Rui (康睿): Non-Executive Director (appointed February 2026)

- Shen Jian'gang (沈剑刚): Independent Non-Executive Director, Professor

- Shen Zuojun (沈佐君): Independent Non-Executive Director, Professor

- He Xin (何欣): Independent Non-Executive Director, PhD (appointed June 2024)

- Jin Tengchuan (金腾川): Independent Non-Executive Director, Professor (appointed February 2026)

- Fan Xiaoliang (范晓亮): Independent Non-Executive Director, Chairman of Audit Committee (appointed July 2025)

Supervisory Board

- Shen Sheng (沈胜): Supervisor, PhD

- Ren Junhe (任君贺): Supervisor

- Fan Hua (范华): Supervisor (appointed June 2024)

Former Leadership

- Wu Lebin (吴乐斌): Former Chairman and Executive Director (removed July 2025); born in 1962; former Vice Director of CAS Institute of Biophysics; founder of the company in 2003; detained by authorities in late 2024

Major Shareholders (As of December 31, 2024)

- Beijing PUSAi Asset Management Co., Ltd. (北京普赛资产管理有限责任公司): 21.64% of total shares (38.93% of domestic shares)

- Hong Kong Zhixin Investment Limited (香港智昕投资有限公司): 18.84% of total shares (42.40% of H-shares); wholly owned by Hainan Zhixin Investment Partnership

- Li Yangyixiong (李杨一雄): 8.29% of total shares (14.91% of domestic shares)

Subsidiaries & Affiliates

- Beijing Zhongsheng Jinyu Diagnostic Technology Co., Ltd. (北京中生金域诊断技术股份有限公司): Shares quoted on the National Equities Exchange and Quotations (NEEQ / New Third Board) in China

- Zhongen (Tianjin) Pharmaceutical Technology Co., Ltd. (中恩（天津）医药科技有限公司): Associate company; BioSino holds 39.21% equity interest

Market Position & Challenges

Centralized Procurement (VBP) Impact

The Chinese IVD market has experienced significant pricing pressure from centralized procurement policies. In 2024 and 2025, the group faced:

- Revenue Decline: FY2025 revenue fell 30% year-on-year due to reduced market demand and significant product price declines

- Margin Compression: Gross margin declined to approximately 39.0% in H1 2025 from higher historical levels

- Impairment Losses: Financial asset impairment of RMB 6.5 million and other asset impairment of RMB 13.0 million in FY2024 due to weaker-than-expected market conditions

Strategic Response

- Customer Relationship Strengthening: Providing one-stop services including instrument maintenance, personnel training, and technical support to major hospital clients

- Market Channel Expansion: Deepening cooperation with primary healthcare institutions and expanding exports to Southeast Asia and other international markets

- Cost Control: Reducing sales, administrative, and R&D expenses in response to revenue decline

Company Overview

Corporate Information

Legal Name (Chinese): 中生北控生物科技股份有限公司

Legal Name (English): Biosino Bio-Technology and Science Incorporation

Founded: April 26, 2001

Headquarters (PRC): No. 27 Chaoqian Road, Changping Science Park, Beijing, China

Hong Kong Office: 66/F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong

Stock Exchange: Hong Kong GEM

Stock Code: 8247

Par Value: RMB 1.00 per H-share

H Shares Issued: 64,286,143 shares

Company Type: Public listed company (H-shares)

Industry: Healthcare / Biotechnology / In-Vitro Diagnostics

Employees: 471 full-time (as of June 30, 2025)

Auditor: BDO Limited (Hong Kong)

Legal Adviser (Hong Kong): Loong & Yeung Solicitors

Principal Bankers: Bank of Beijing, Agricultural Bank of China, Bank of China (Hong Kong), Industrial Bank

Website: www.zhongsheng.com.cn

Email: bjzhsh@public3.bta.net.cn; jishuzu@zhongsheng.com.cn

Telephone: +86-10-64840910; +86-10-80107541

Fax: +86-10-64840920

2026 Strategic Outlook

- Leadership Stability: Under Chairman Chen Peng, restore stable corporate governance and investor confidence following the 2024–2025 leadership crisis

- Market Recovery: Navigate the challenging IVD centralized procurement environment and seek revenue stabilization

- Product Innovation: Continue R&D investment in clinical chemistry and immunoassay reagents to maintain competitiveness

- International Expansion: Expand export sales in Southeast Asia and other emerging markets through local distributor partnerships

- Laboratory Excellence: Leverage the newly acquired CNAS accreditation to strengthen reference laboratory capabilities and brand reputation

Contact Information

China Headquarters

Address: No. 27 Chaoqian Road, Changping Science Park, Beijing, China

TEL: +86-10-64840910 / +86-10-80107541

FAX: +86-10-64840920

Email: bjzhsh@public3.bta.net.cn; jishuzu@zhongsheng.com.cn

Website: www.zhongsheng.com.cn

Hong Kong Office

Address: 66/F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong

Company Secretary: Mr. Tung Woon Cheung Eric (董涣樟), CPA

Investor Relations

Hong Kong Share Registrar: Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

Keywords: BioSino, Biosino Bio-Technology And Science Inc, 中生北控, 8247, IVD, in-vitro diagnostics, clinical chemistry reagents, diagnostic reagents, liver function, renal function, lipids, cardiac markers, glucose metabolism, Beijing, China, Hong Kong GEM, Chen Peng, Chen Zhengyong, Wu Lebin, NEEQ, CNAS, centralized procurement, VBP, biochemical reagents, immunoassay, ELISA, medical inspection